









Markets
/
Stocks
/
nasdaq-nyxh
/

Nyxoah SA

NYXH

4.940USD

+0.160+3.35%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

184.93MMarket Cap

LossP/E TTM



Nyxoah SA

4.940

+0.160+3.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

100 / 207

Overall Ranking

217 / 4720

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

13.200

Target Price

+176.15%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 51.54% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.37M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 96.10.

Overvalued

The company’s latest PE is -2.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 25.16M shares, decreasing 10.70% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.28.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.83, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.14M, representing a year-over-year increase of 57.98%, while its net profit experienced a year-over-year increase of 42.72%.

Score

Industry at a Glance

Previous score

5.83

Change



Financials

7.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.45

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -2.26, which is 92.27% below the recent high of -4.35 and -153.08% above the recent low of -5.72.

Score

Industry at a Glance

Previous score

2.80

Change

1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 100/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Nyxoah SA is 13.00, with a high of 15.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

13.200

Target Price

+176.15%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Nyxoah SA

NYXH

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.40, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 6.07 and the support level at 4.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.40

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.113

Sell

RSI(14)

31.055

Neutral

STOCH(KDJ)(9,3,3)

20.050

Buy

ATR(14)

0.299

Low Volatility

CCI(14)

-65.833

Neutral

Williams %R

75.796

Sell

TRIX(12,20)

-1.256

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.760

Buy

MA10

5.169

Sell

MA20

5.654

Sell

MA50

6.640

Sell

MA100

6.962

Sell

MA200

7.947

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cochlear Limited

5.63M

Taub (Robert)

3.98M

+17.27%

Monden (Anneliese)

2.94M

Gilde Healthcare Partners B.V.

2.94M

ResMed Inc

1.73M

Vestal Point Capital, LP

1.81M

-21.95%

Hambrecht (Jürgen)

1.34M

BNP Paribas Asset Management Belgium S.A.

792.37K

BlackRock Financial Management, Inc.

965.58K

-11.85%

Fidelity Management & Research Company LLC

1.11M

-36.82%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.17, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.